Can mRCC Patients Be Spared Debulking Nephrectomy?

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Dr. Daniel George discusses CARMENA, which asked if cytoreductive surgery is necessary in the age of active systemic therapy for mRCC.

In this video, Dr. Daniel George discusses CARMENA, which asked if cytoreductive surgery is necessary in the age of active systemic therapy for mRCC.

Recent Videos
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Related Content
Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC

Russ Conroy
October 25th 2025
Article

Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.

ROS1-Targeting Therapies Show “Suboptimal” Efficacy in ROS1-Mutated NSCLC

Roman Fabbricatore
October 24th 2025
Article

Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Approximately half of the patients who received raludotatug deruxtecan in the phase 2/3 REJOICE-Ovarian01 trial achieved an objective response.

Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer

Jason M. Broderick
October 21st 2025
Article

Approximately half of the patients who received raludotatug deruxtecan in the phase 2/3 REJOICE-Ovarian01 trial achieved an objective response.

Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Gina Mauro
October 21st 2025
Article

The BURAN trial revealed no overall survival benefit for buparlisib and paclitaxel in recurrent head and neck cancer, despite some response rate improvements.